JP2021535193A - 新型構造の抗vegf−抗pd1二重特異性抗体 - Google Patents
新型構造の抗vegf−抗pd1二重特異性抗体 Download PDFInfo
- Publication number
- JP2021535193A JP2021535193A JP2021526420A JP2021526420A JP2021535193A JP 2021535193 A JP2021535193 A JP 2021535193A JP 2021526420 A JP2021526420 A JP 2021526420A JP 2021526420 A JP2021526420 A JP 2021526420A JP 2021535193 A JP2021535193 A JP 2021535193A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- vegf
- seq
- cdr
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (10)
- 新型構造の抗VEGF−抗PD1二重特異性抗体であって、前記抗体の重鎖可変領域のCDR−H1が、SEQ ID NO:1で表されるアミノ酸配列であり、CDR−H2が、SEQ ID NO:2で表されるアミノ酸配列であり、CDR−H3が、SEQ ID NO:3で表されるアミノ酸配列であり、前記抗体の軽鎖可変領域のCDR−Lが、SEQ ID NO:4で表されるアミノ酸配列である新型構造の抗VEGF−抗PD1二重特異性抗体。
- 前記抗体の重鎖可変領域のCDR−H1が、SEQ ID NO:5で表されるヌクレオチド配列であり、CDR−H2が、SEQ ID NO:6で表されるヌクレオチド配列であり、CDR−H3が、SEQ ID NO:7で表されるヌクレオチド配列であり、前記抗体の軽鎖可変領域のCDR−Lが、SEQ ID NO:8で表されるヌクレオチド配列である請求項1に記載の新型構造の抗VEGF−抗PD1二重特異性抗体。
- 前記抗体の重鎖定常領域の配列が、ヒトIgG1の重鎖定常領域配列であり、軽鎖定常領域の配列が、ヒトk抗体の軽鎖定常領域配列である請求項1に記載の新型構造の抗VEGF−抗PD1二重特異性抗体。
- 前記抗体の重鎖アミノ酸配列が、SEQ ID NO:9で表される請求項1に記載の新型構造の抗VEGF−抗PD1二重特異性抗体。
- 前記抗体の軽鎖アミノ酸配列が、SEQ ID NO:10で表される請求項1に記載の新型構造の抗VEGF−抗PD1二重特異性抗体。
- 前記抗体の重鎖ヌクレオチド配列が、SEQ ID NO:11で表される請求項2に記載の新型構造の抗VEGF−抗PD1二重特異性抗体。
- 前記抗体の軽鎖ヌクレオチド配列が、SEQ ID NO:12で表される請求項2に記載の新型構造の抗VEGF−抗PD1二重特異性抗体。
- 請求項1〜7のいずれか1項に記載の抗体および薬剤的に許容可能なキャリアを含む医薬組成物。
- 請求項1〜7のいずれか1項に記載の前記抗体のVEGFとPD1の活性を抑制または中和する医薬の作製における用途。
- 前記VEGFとPD1の活性を抑制または中和する医薬が、癌の治療に使用される請求項9に記載の用途。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/099989 WO2021026685A1 (zh) | 2019-08-09 | 2019-08-09 | 一种新型结构的抗vegf-抗pd1双特异性抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021535193A true JP2021535193A (ja) | 2021-12-16 |
JP7052149B2 JP7052149B2 (ja) | 2022-04-11 |
Family
ID=74570821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021526420A Active JP7052149B2 (ja) | 2019-08-09 | 2019-08-09 | 新型構造の抗vegf-抗pd1二重特異性抗体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11661454B2 (ja) |
JP (1) | JP7052149B2 (ja) |
AU (1) | AU2019461286B2 (ja) |
DE (1) | DE112019005626T5 (ja) |
WO (1) | WO2021026685A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024032662A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105111314A (zh) * | 2015-08-13 | 2015-12-02 | 成都百世博生物技术有限公司 | 一种新型融合蛋白、药物组合物及其制备方法和用途 |
CN105175545A (zh) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
JP2019506863A (ja) * | 2016-02-02 | 2019-03-14 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Pd−l1及びkdrに対する二重結合タンパク質 |
CN109575140A (zh) * | 2017-09-29 | 2019-04-05 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199902818T2 (xx) | 1997-04-07 | 2000-05-22 | Genentech, Inc. | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. |
US10617755B2 (en) * | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
CN105175544B (zh) | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
US11059885B2 (en) * | 2016-05-13 | 2021-07-13 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
CN106519034B (zh) * | 2016-12-22 | 2020-09-18 | 鲁南制药集团股份有限公司 | 抗pd-1抗体及其用途 |
-
2019
- 2019-08-09 AU AU2019461286A patent/AU2019461286B2/en active Active
- 2019-08-09 US US16/980,853 patent/US11661454B2/en active Active
- 2019-08-09 DE DE112019005626.3T patent/DE112019005626T5/de active Pending
- 2019-08-09 JP JP2021526420A patent/JP7052149B2/ja active Active
- 2019-08-09 WO PCT/CN2019/099989 patent/WO2021026685A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105111314A (zh) * | 2015-08-13 | 2015-12-02 | 成都百世博生物技术有限公司 | 一种新型融合蛋白、药物组合物及其制备方法和用途 |
CN105175545A (zh) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
JP2019506863A (ja) * | 2016-02-02 | 2019-03-14 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Pd−l1及びkdrに対する二重結合タンパク質 |
CN109575140A (zh) * | 2017-09-29 | 2019-04-05 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
Also Published As
Publication number | Publication date |
---|---|
DE112019005626T5 (de) | 2021-08-05 |
US11661454B2 (en) | 2023-05-30 |
US20210403563A1 (en) | 2021-12-30 |
WO2021026685A1 (zh) | 2021-02-18 |
AU2019461286B2 (en) | 2024-01-04 |
JP7052149B2 (ja) | 2022-04-11 |
AU2019461286A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110498857B (zh) | 一种抗vegf-抗pd1双特异性抗体 | |
CN112794909B (zh) | 一种抗tigit单克隆抗体及其应用 | |
WO2016197497A1 (zh) | 一种抗pd-1的单克隆抗体及其获得方法 | |
CN107488229B (zh) | Pd-l1抗体及其用途 | |
CN110563849B (zh) | 一种抗vegf-抗pd1双特异性抗体 | |
US9580498B2 (en) | Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial growth factor to its receptor, and coding sequence | |
CN108124445A (zh) | Ctla4抗体、其药物组合物及其用途 | |
JP7229419B2 (ja) | ヒト化抗vegf fab抗体断片及びその使用 | |
CN112041347A (zh) | 结合人il-4r的抗体、其制备方法和用途 | |
JP2022153281A (ja) | PD-1とTGF-betaを標的とした四価二重特異性抗体、その製造方法および用途 | |
JP7052149B2 (ja) | 新型構造の抗vegf-抗pd1二重特異性抗体 | |
CN112521508B (zh) | 一种cd20抗体及其治疗癌症的应用 | |
CN110713538A (zh) | 一种抗人cd28单克隆抗体及其用途 | |
CN113234160B (zh) | 一种抗pd-1抗体及其应用 | |
RU2809746C2 (ru) | Гуманизированное моноклональное антитело против vegf | |
CN112521499B (zh) | 抗cxcl13抗体及其用途 | |
WO2023198019A1 (zh) | 一种抗ceacam5和ceacam6抗体及其应用 | |
WO2023193732A1 (zh) | 一种抗ccr8抗体或其抗原结合片段 | |
US20230257469A1 (en) | TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN | |
CN117586408A (zh) | 一种结合tnfr2和b7h3的双特异性抗体 | |
KR20220087488A (ko) | Pd-l1 결합 분자 | |
CN114249827A (zh) | 抗tigit抗体及双抗体和它们的应用 | |
CN110724195A (zh) | 一种抗人icos单克隆抗体 | |
CN112851810A (zh) | Cd20抗体及其治疗癌症的应用 | |
CN113621066A (zh) | 一种抗pd-1抗体及其晶体制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210512 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220310 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220330 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7052149 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |